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Abstract 
Background: Fatty acids and lipid mediator signaling play an important role in the 
pathogenesis of asthma, yet this area remains largely under-explored. The aims of this study 
were (i) to examine fatty acid levels and their metabolism in obese and non-obese asthma 
patients and (ii) to determine the functional effects of altered fatty acid metabolism in 
experimental models.  
Methods: Medium- and long-chain fatty acid levels were quantified in serum from 161 
human volunteers by LC/MS. Changes in stearoyl-coenzyme A desaturase (SCD) expression 
and activity was evaluated in the ovalbumin (OVA) and house dust mite (HDM) murine 
models. Primary human bronchial epithelial cells from asthma patients and controls were 
evaluated for SCD expression and activity. 
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Results: The serum desaturation index (an indirect measure of SCD) was significantly 
reduced in non-obese asthma patients and in the OVA murine model. SCD1 gene expression 
was significantly reduced within the lungs following OVA or HDM challenge. Inhibition of 
SCD in mice promoted airway hyperresponsiveness. SCD1 expression was suppressed in 
bronchial epithelial cells from asthma patients. IL-4 and IL-13 reduced epithelial cell SCD1 
expression. Inhibition of SCD reduced surfactant protein C expression and suppressed 
rhinovirus-induced IP-10 secretion, which was associated with increased viral titers.  
Conclusions: This is the first study to demonstrate decreased fatty acid desaturase activity in 
humans with asthma. Experimental models in mice and human epithelial cells suggest that 
inhibition of desaturase activity leads to airway hyperresponsiveness and reduced anti-viral 
defense. SCD may represent a new target for therapeutic intervention in asthma patients. 
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Abbreviations 
ACC, acetyl-coA carboxylase; ALI, air liquid interface; ATRA, all trans retinoic acid; 
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10; MUFAs, monounsaturated fatty acids; OVA, ovalbumin; PUFAs, polyunsaturated fatty 
acids; RNA, ribonucleic acid; SCD, stearoyl-coenzyme A desaturase; SFAs, saturated fatty 
acids; TEER, trans-epithelial resistance.  
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Introduction 
Fatty acid levels and their metabolism can have significant effects on immune cell 
polarization and inflammatory responses. For example, the metabolism of arachidonic acid 
by cyclooxygenase enzymes leads to the production of prostaglandins, leukotrienes, and other 
bioactive eicosanoids, which all have significant effects on the immune system (1-3). Indeed, 
in obese individuals, an increase in circulating free fatty acids driven by the metabolic 
overload has been demonstrated to affect immune cells and chronic inflammatory processes 
(4). Certain fatty acids, e.g. n-3 polyunsaturated fatty acids (PUFAs) or monounsaturated 
fatty acids (MUFAs), can potentially decrease inflammation through several mechanisms, 
while saturated fatty acids (SFAs) may contribute to the magnitude of proinflammatory 
responses (5-7). The balance between pro- and anti-inflammatory fatty acids is increasingly 
thought to be important in many chronic inflammatory disorders. 
It is not only the fatty acid levels themselves that are important, but also the 
endogenous metabolism of fatty acids, e.g. by elongation and desaturation, will influence 
their effects in the body. The plasma fatty acid desaturation index (MUFA/SFA ratio) 
indirectly assesses stearoyl-CoA desaturase (SCD) activity. The SCD enzyme is a rate-
limiting enzyme in the synthesis of MUFAs (8) and SCD mutations were identified as the 
source of the asebia phenotype in mice (9). SCD plays an important role in whole-body 
energy balance. Notably, skin-specific SCD deletion resulted in increased whole-body energy 
expenditure, protection against diet-induced adiposity, hepatic steatosis and glucose 
intolerance, thus linking cutaneous lipid metabolism to whole-body energy balance (10). 
SCD has also been implicated in the regulation of adipocyte inflammation, macrophage 
inflammation, myocyte and endothelial cell function (11). 
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Impaired fatty acid metabolism has been previously proposed to contribute to the 
pathogenesis of asthma (12-14). One asthma endotype, which frequently presents with more 
severe clinical features and corticosteroid resistance, is associated with obesity (15-18). 
Weight loss in obese asthmatics can substantially impact asthma symptoms and airway 
hyperresponsiveness (19). However, it is likely that metabolic factors, such as free fatty 
acids, could play a role in the development of asthma in obese and non-obese individuals. In 
this study we quantified free fatty acid levels in obese and non-obese asthma patients. 
Circulating levels of many fatty acids were increased in obese patients, but surprisingly we 
found that the desaturation index was significantly lower in non-obese asthma patients, 
suggesting reduced SCD activity in non-obese asthma patients. Follow-on studies in animal 
models and primary human bronchial epithelial cells provide additional functional support for 
the protective role of this enzyme within the lung.  
 
Methods 
Patient groups 
This was an observational study in which 161 volunteers were recruited in 4 groups – 
obese asthma (n=40), obese non-asthma (n=40), non-obese asthma (n=41) and non-obese 
non-asthma healthy controls (n=40). Asthma patients were recruited only if they had a 
diagnosis of asthma made by a physician. Severe asthma was defined according to the 
American Thoracic Society (ATS) Workshop on Refractory Asthma 2000 report and by the 
2013 European Respiratory Society (ERS)/ATS guidelines (20, 21). A patient was included 
to the severe asthma group if he/she fulfilled one or both major and at least two minor ATS 
2000 criteria. Patients who did not fulfill these criteria were included in the mild-to-moderate 
asthma group. Obesity was defined as having a body mass index (BMI) greater than 30 
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kg/m2. Non-obese individuals had a BMI of 20-25 kg/m2. Exclusion criteria were age < 18 
or > 65 years, acute infection within 4 weeks of sampling, significant acute or chronic 
coexisting illness or a condition which contraindicates involvement in the study, malignant or 
any concomitant end stage organ disease, the use of experimental drugs or the participation in 
another research study within the past 30 days. Ethical approval was granted at the two 
recruitment centers (KB-329/2013 and KEK-ZH-Nr. 2012-0443) and all volunteers signed an 
informed consent. The human biological samples were sourced ethically and their research 
use was in accord with the terms of the informed consents. Venous whole blood was drawn 
from the study participants into tubes without anti-coagulant (BD Biosciences, New Jersey, 
USA). The tubes were allowed to stand for 2 hours and serum was obtained by centrifuging 
blood at 800 g for 10 min and was stored at −80 °C until analysis.   
 
Medium- and long-chain fatty acid determination in serum by LC/MS. 
Analysis of fatty acids in serum was performed by extraction, derivatization, and 
analysis by liquid chromatography coupled to mass spectrometry (LC/MS) using the 
corresponding deuterated fatty acids as internal standards, as previously described with some 
modifications (22, 23). 20 µL of the mixture of deuterated internal standards at a 
concentration of 50 µM in EtOH ─ decanoic acid-d5, undecanoic acid-d3, dodecanoic acid-d5, 
tetradecanoic acid-d5, pentadecanoic acid-d3, hexadecanoic acid-d5, and octadecanoic acid-d5 
(CDN Isotopes, France), as well as palmitoleic acid-d14, oleic acid-d17, α-linolenic acid-d14, 
arachidonic acid-d8 and docosahexaenoic-d5, (Cayman Europe, Estonia) ─ were added to 
serum samples (250 µL) together with 1 mL of 0.05% H2SO4 (v/v aqueous), and 3 mL of 
ethyl acetate. The mixture was vortexed and centrifuged. The aqueous phase was discarded 
and the organic layer was evaporated under a stream of nitrogen. The dried samples were 
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treated with 300 µL of oxalyl chloride (2 M in dichloromethane, Sigma-Aldrich, Spain) and 
incubated at 65 ºC for 5 min. Samples were evaporated under a nitrogen stream and treated 
with 250 µL of 3-picolylamine (Sigma-Aldrich, Spain, 1% v/v in acetonitrile). The samples 
were incubated at room temperature for 5 min, evaporated under a nitrogen stream and 
reconstituted in 300 µL of EtOH, 80 µL of which were analyzed by LC/MS. LC/MS analysis 
was performed using an Agilent 1200LC-MSD VL instrument. LC separation was achieved 
with an Agilent Poroshell 120, SB-C18 column (Agilent, Spain, 2.7 µm, 2.1x50mm) together 
with a guard column Poroshell 120, UHPLC Guard, SB-C18, (Agilent). The gradient elution 
mobile phase consisted of A (95:5 water:acetonitrile) and B (95:5 acetonitrile:water) with 
0.1% formic acid as the solvent modifier. MS analysis was performed with an electrospray 
ionization (ESI) source. Fractions were quantified by measuring the area under the peak 
relative to the corresponding deuterated standard. In all cases, control experiments, with 
serum enriched with each of the fatty acid under study, were performed to rule out the 
presence of other metabolites with the same molecular weight or retention time. 
 
Murine models 
Female BALB/c mice aged 6-8 weeks were obtained from Charles River (Sulzfeld, 
Germany) housed and maintained under specific pathogen free conditions at the AO Research 
Institute, Davos, Switzerland, in individually ventilated cages for the duration of the study. 
All animal studies were ethically reviewed and carried out in accordance with European 
Directive 86/609/EEC and the GSK Policy on the Care, Welfare and Treatment of Animals. 
Experimental procedures were approved by the animal experiment commission of the canton 
Grisons, Switzerland. Three intraperitoneal immunizations with 20 µg of OVA grade VI 
(Sigma, Buchs, Switzerland) emulsified in 500 µg Imject™ Alum Adjuvant (Pierce, 
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Rockford, IL, USA) in 200 µl sterile 0.9 % isotonic Sodium chloride (NaCl) were performed 
on days 0, 14 and 21, followed by 1 % OVA grade V (Sigma-Aldrich, Buchs, Switzerland) 
aerosol challenges on days 26, 27 and 28. Mice were euthanized at day 29 for isolation of 
lung tissue and serum extraction. 
In addition, female C57Bl/6 mice (6-8 weeks) were obtained from Charles River  and 
were sensitized intranasally (i.n.) with 1 μg of house dust mite extract (HDM, Greer 
Laboratories, Lenoir, NC) or NaCl on day 0 and challenged with 10 μg of HDM on days 7-11 
before they were analyzed at day 14 for isolation of lung tissue and serum extraction. 
Finally, Balb/c mice (from Charles River) were gavaged daily, for 15 days, with 200 
µl of NaCl or NaCl containing 0.06mg of the SCD-1 inhibitor MF-438 (Focus Biomolecules, 
PA, USA). On day 16 mice were intubated under anesthesia and airway resistance was 
assessed using the FlexiVent system (SCIREQ, Montreal, Canada). Airway resistance was 
measured in response to increasing concentrations of methacholine (Sigma-Aldrich). 
 
Gene Expression Analysis 
RNA from murine lung tissue or bronchial epithelial cell cultures was isolated using 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands). Reverse transcription of 200 ng RNA was 
performed with RevertAid RT according to manufacturer instructions (Thermo Fisher 
Scientific Kit, Waltham, MA USA). Real time PCR was performed with iTaq SYBR Green 
Supermix (Bio-Rad Laboratories, Hercules, USA) on an Applied Biosystems 7900 HT Fast 
Real-Time PCR system. The cycling conditions were as follows: 50°C for 2 min, 95°C for 10 
min, 40 cycles 95°C for 15 sec, 60°C for 1 min, plus an additional step for the dissociation 
curve. The primers used are listed in Table S1 (in this article’s Online Repository) and all 
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were synthesized by Microsynth (Balgach, Switzerland). The relative expression of each gene 
was normalized according to the ΔΔCT method. 
 
Bronchial epithelial cell culture 
Primary human bronchial epithelial cells were purchased from Lonza (Basel, 
Switzerland) or were generated from bronchial brushings of asthmatic patients and control 
subjects, as previously described (24). Cells were cultured as monolayers in Bronchial 
Epithelial Cell Growth Medium (BEGM; Lonza, Basel, Switzerland) containing Bronchial 
Epithelial Basal Medium plus all the bullet-kit singlequots at 37°C in a humidified 
atmosphere at 5% CO2. Medium was changed every second day. Cells were seeded at a 
density of 75,000 cells in a 6.5-mm-diameter polyester membrane with a pore size of 0.4 mm 
(Corning Costar, Corning, NY) in BEGM medium. Once confluent, the medium in the apical 
compartment was removed and the medium in the basal compartment was substituted with 
ALI medium (Dulbecco modified Eagle medium [Gibco-BRL, Invitrogen] mixed 1:1 with 
BEGM supplemented with ATRA 50 nM to allow the cells to differentiate as air liquid 
interface (ALI) cultures.  Trans-epithelial resistance (TEER) was monitored using a Millicell-
ERS Volt-Ohm Meter (Millipore, Temecula, CA, USA). SCD1 levels were quantified in cell 
lysates using an ELISA. The primary anti-SCD1 antibody and secondary HRP conjugated 
goat anti-mouse antibody were obtained from Abcam (Cambridge, MA, USA). 
ALI culture cells were stimulated with the cytokine Th2 cocktail IL-4 and IL-13 
(Peprotech, Rocky Hill, USA) at a dose of 10 ng/mL for each cytokine in the basolateral 
compartment. In addition, ALI cultures were treated with 10 nM of the SCD inhibitor MF-
438 (FOCUS Biomolecules), which was also added to the basolateral compartment. After 4 
hours incubation with MF-438, cells were apically exposed for 2 hours to rhinovirus at a MOI 
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of 10 (HRV16; Virapur, San Diego, USA). The apical surface was washed twice with PBS 
and all remaining liquid removed. Epithelial cell viral titer was quantified using a PCRmax 
qPCR kit for HRV16, according to manufacturer’s instructions. Supernatant IP-10 levels 
were quantified using a Bio-Plex kit (Bio-Rad, Hercules, USA). 
 
Statistical analysis  
Graphing and statistical analysis was performed using Prism 5 (Graph Pad Software, 
San Diego, CA, USA). Differences between more than two groups were analyzed for 
statistical significance using one-way ANOVA followed by post hoc analysis. Differences 
between two groups were analyzed using the Mann–Whitney U test. P-values less than 0.05 
were considered statistically significant. 
Results 
Obesity is associated with elevated circulating levels of fatty acids 
Patient demographic and clinical details are included in Table 1. Serum levels of the 
fatty acids myristic acid (tetradecanoic acid, C14:0), pentadecanoic acid (C15:0) and stearic 
acid (octadecanoic acid, C18:0) were significantly elevated in obese non-asthma patients 
compared to non-obese non-asthma controls, while a similar non-statistically significant trend 
was observed for obese asthma patients compared to non-obese asthma patients (Fig. 1). 
Palmitic acid (hexadecanoic acid, C16:0), palmitoleic acid (C16:1), α-linolenic acid (C18:3) 
and docosahexaenoic acid (C22:6) were significantly elevated in both the obese non-asthma 
and obese asthma patients compared to their respective non-obese controls (Fig. 1). Serum 
arachidonic acid (C20:4) levels were significantly higher in obese asthma patients compared 
to non-obese asthma patients, while no differences were observed between obese and non-
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obese non-asthma controls (Fig. 1). Serum levels of capric acid (decanoic acid C10:0), 
undecanoic acid (C11:0) and lauric acid (dodecanoic acid, C12:0) were similar for all groups 
(Fig. S1 in this article’s Online Repository). 
We next determined if serum fatty acid levels were associated with any of the patient 
clinical parameters. Interestingly, serum levels of palmitoleic acid, arachidonic acid and 
docosahexaenoic acid were significantly reduced in non-obese asthma patients with severe 
disease (Fig. 2A), which was not observed in obese asthma patients. In addition, the serum 
desaturation index (palmitoleic:palmitic ratio) was significantly suppressed in non-obese 
severe asthma patients, with a trend towards reduced levels in mild/moderate non-obese 
asthma patients, which was not observed in obese asthma patients (Fig. 2B). The serum 
desaturation index did not correlate with the use or dose of steroids or LABAs (Fig. S2 in this 
article’s Online Repository). 
 
SCD activity is suppressed in murine models of allergic airway inflammation 
 To better understand the relevance of the suppressed desaturation index observed in 
non-obese asthma patients, we quantified the desaturation index in mice that were sensitized 
and challenged with ovalbumin. Similar to the observation in humans, the C16:1 to C16:0 
ratio was significantly reduced in the mouse model (Fig. 3A). To confirm this result, the 
desaturation index using the C18:1 to C18:0 ratio was also calculated. The results were 
identical (Fig. 3B), suggesting that the metabolism of fatty acids changes following the 
induction of allergic airway inflammation. The desaturation index reflects the expression and 
activity of SCD enzymes. Thus the gene expression of the two major murine SCD isoforms, 
SCD1 and SCD2 in the murine lung and liver was quantified. SCD1 and SCD2 gene 
expression were both significantly decreased in the lungs of ovalbumin challenged animals 
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(Fig. 3C and 3D), while they remained unchanged in the liver (Fig. S3 in this article’s Online 
Repository). In addition, SCD1 and SCD2 gene expression were further decreased in the lung 
following challenge with house dust mite extract (Fig. 3C and 3D). This data suggests that 
the systemic suppression of the desaturation index, which reflects suppressed SCD activity, 
may be at least partially due to a allergic inflammation-induced decrease in SCD activity 
within the lung. 
 As decreased SCD activity correlates with the presence of airway inflammation, both 
in humans and mice, the functional consequences for the lung following inhibition of SCD 
activity was determined. Mice were administered an SCD-1 inhibitor, MF-438, for 15 days 
and thereafter airway hyper-responsiveness in response to methacholine challenge was 
assessed. With increasing doses of methacholine, MF-438-treated animals displayed 
significant defects in tissue elasticity and tissue dampening (Fig. 3E and 3F). The 
measurement of tissue elastance reflects the energy conservation in the alveoli while the 
tissue dampening measurement is closely related to tissue resistance and reflects the energy 
dissipation in the alveoli. 
 
SCD expression is altered in bronchial epithelial cells from asthma patients 
SCD gene expression was quantified in primary bronchial epithelial cells from healthy 
donors (n=4) and asthma patients (n=9). Expression of the two human SCD isoforms, SCD1 
and SCD5, was significantly lower in epithelial cells from asthma patients compared to 
healthy volunteers (Fig. 4A and 4B). In addition to SCD expression, the gene expression of 
other enzymes involved in fatty acid metabolism was quantified. Acetyl-CoA carboxylase 
(ACC) catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, while fatty acid synthase 
(FAS) catalyzes the synthesis of palmitic (C16:0) from malonyl-CoA. There was no 
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difference in ACCalpha gene expression, but ACCbeta was significantly upregulated and FAS 
significantly downregulated in bronchial epithelial cells from asthma patients (Fig. S4 in this 
article’s Online Repository). This data suggests that fatty acid metabolism is significantly 
disturbed in epithelial cells from asthma patients. 
In order to model the cytokine environment of the asthmatic lung, bronchial epithelial 
cells from healthy donors were incubated with IL-4 and IL-13 for 24 hours. This cytokine 
cocktail suppressed SCD1 gene expression and reduced SCD1 protein levels in cell lysates 
(Fig. 4C).  In addition, bronchial epithelial cells from healthy donors were co-incubated with 
the SCD1 inhibitor, MF-438. SCD1 inhibition did not alter TEER or epithelial cell viability. 
However, MF-438 significantly reduced surfactant protein C gene expression, with no effect 
on surfactant protein D expression (Fig. 4D). Lastly, bronchial epithelial cells were infected 
with rhinovirus (RV16) following treatment with MF-438. Inhibition of SCD1 significantly 
reduced epithelial cell IP-10 secretion in response to rhinovirus infection, which was 
associated with an increase in viral titer (Fig. 4E and 4F). 
Discussion 
Asthma is characterized by recurrent and reversible airflow obstruction with airway 
inflammation central to its pathogenesis (25). However, successful management of patients 
with asthma continues to be problematic due to the heterogeneity of the disease with different 
phenotypes and endotypes continuingly being described (26). In this study, we describe 
significant differences in circulating fatty acids levels in patients with obese and non-obese 
asthma. In particular, non-obese patients with severe disease had significantly reduced serum 
fatty acid levels. In addition, a suppressed MUFA:SFA ratio suggested reduced desaturase 
activity. Similar to humans, murine models of respiratory allergic inflammation also showed 
reduced desaturase activity, which correlated with diminished SCD expression in the lung. 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Inhibition of SCD had negative effects on lung physiology in the mouse and on primary 
human bronchial epithelial cell responses in vitro. 
Our results showing increased serum levels of many different fatty acids in obese 
individuals is consistent with existing published reports (27). Similarly, serum fatty acid 
levels were elevated in obese asthma patients compared to non-obese asthma patients. 
However, the reduction in MUFAs and PUFAs serum levels were only observed in non-obese 
asthma patients with severe disease and not in obese asthma patients with severe disease. 
This may suggest a different inflammatory process within the lungs of obese versus non-
obese asthma patients, associated with altered metabolism of these fatty acids. Alternatively, 
dietary differences associated with obesity may compensate for the loss of these fatty acids 
from the circulation in obese patients with severe asthma. Supplementation of non-obese 
severe asthma patients with MUFAs or PUFAs may help to restore the availability of these 
important fatty acids. Clinical studies do show a modest improvement in asthma symptoms 
following fatty acid supplementation, but truly efficacious treatment schedules are still 
lacking (28-30).  
Further evidence for altered metabolism of fatty acids in non-obese versus obese 
asthma patients was suggested by the reduced desaturation index in non-obese patients. The 
SCD enzyme that determines the desaturation index has previously been shown to be 
important for maintenance of a healthy skin barrier. SCD1 deficient mice exhibit a severe 
skin phenotype that includes alopecia, atrophy of sebaceous glands, dermatitis and increased 
permeability of the skin barrier (31). These skin defects were associated with a dramatically 
altered skin lipid profile and reduced the immunological response to effectively protect 
against skin-associated bacterial infection (32). Our data now extends the effect of SCD1 
blockade to the lung, whereby pharmacological inhibition promoted airway 
hyperresponsiveness in vivo and dampened anti-viral responses in vitro.  Altered expression 
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of surfactant protein C in cultured epithelial cells suggested that SCD may support the 
production of pulmonary surfactant that increases the compliance of the lungs by reducing 
surface tension. The influence of SCD on the epithelial response to rhinovirus is in line with 
other reports demonstrating a connection between lipid mediator production and anti-viral 
responses (33). However, further studies are required to fully address the in vivo role of SCD 
in surfactant production and anti-viral defense within the lung of asthma patients. 
 Our data suggests that SCD gene expression and the desaturation index may be 
regulated by inflammatory responses within the lung. We observed decreased lung SCD gene 
expression in two different murine models of respiratory inflammation (OVA and HDM 
models) and cytokines such as IL-4 and IL-13 suppress SCD expression in cultured human 
bronchial epithelial cells. The suppressed desaturation index observed in humans does not 
seem to be related to the use of corticosteroids as there was no relationship between steroid 
dose and the index value. In addition, corticosteroids were not used in the murine models. 
Lastly, we cannot rule out the possibility that SCD gene variants may contribute to a genetic 
susceptibility to develop more severe airway inflammatory responses. No information is 
currently available on SCD polymorphisms in asthma. However, a recent genome-wide 
association study of peripheral blood CD4+ lymphocytes did identify a locus within the Fatty 
Acid Desaturase gene (FADS1/FADS2) on 11q, which was associated with asthma 
susceptibility (34). FADS1 and FADS2 encode for Δ5- and Δ6-desaturase enzymes 
respectively, while SCD is a Δ9-desaturase. Thus, while these enzymes have different targets, 
this study also implies that inappropriate fatty acid desaturation may play an important role in 
the development of inflammation within the airways. 
 In conclusion, fatty acid desaturase activity is reduced in non-obese asthma patients. 
The functional importance of this change in enzymatic activity will need to be confirmed and 
further expanded in future studies, but our observations suggest that fatty acid desaturase 
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activity should be considered an important biological process that contributes to lung 
inflammatory and immune responses. Significant differences in obese asthmatics compared 
to non-obese asthmatics continue to be described, further supporting the differential diagnosis 
and treatment of these asthma endotypes (35-38). 
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Figure Legends 
Figure 1 Serum fatty acid levels are elevated in obese volunteers.  
Myristic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, stearic acid, α−linolenic 
acid, arachidonic acid and docosahexaenoic acid were measured in serum samples from 
obese and non-obese asthma and non-asthma subjects.  
*P < 0.05; **P < 0.01 
 
Figure 2 Disease severity influences serum fatty acid levels 
Serum levels of palmitoleic acid, arachidonic acid and docosahexaenoic acid (A) are 
significantly decreased in non-obese, but not obese, asthma patients with severe disease. In 
addition, the serum desaturation index (palmitoleic/palmitic acid ratio) was significantly 
suppressed in the non-obese severe asthma patients (B). 
*P < 0.05; **P < 0.01 
 
Figure 3 SCD expression and activity is downregulated in murine  models of  airway 
inflammation.  
The desaturation index, calculated as palmitoleic/palmitic acid ratio (A) or stearic/oleic acid 
ratio (B) was suppressed in OVA sensitized and challenged mice (n=8-10 mice per group). 
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Relative SCD1 (C) and SCD2 (D) gene expression was reduced in the lungs of OVA or HDM 
challenged animals (at least 6 mice and included per group). Methacholine-induced lung 
elasticity (E) and dampening (F) are increased in mice treated with the SCD inhibitor MF-438 
(n=8 mice per group). 
*P < 0.05 
 
Figure 4 SCD in human bronchial epithelial cells. 
(A) SCD1 and (B) SCD5 gene expression are significantly reduced in bronchial epithelial 
cells from asthma patients (AHBE, n=9 donors) compared to healthy volunteers (NHBE, n=6 
donors). (C) IL-4 and IL-13 reduce the levels of SCD1 in NHBE epithelial cells (n=6 
donors). (D) The SCD inhibitor MF-438 significantly reduced surfactant protein C (SftpC) 
gene expression, with no effect on surfactant protein D expression (StfpD), n=3 NHBE 
donors. Rhinovirus (RV16) induced less IP-10 secretion (E) but replicated better (F) in MF-
438 treated NHBE cells, n=3 donors.  
*P < 0.05 
 
Figure S1 Unaltered serum fatty acids. 
Figure S2 The serum desaturation index does not correlate with dose of steroids or LABAs 
used. 
Figure S3 SCD1 gene expression is not altered in liver tissue of murine models of allergic 
airway inflammation. 
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Figure S4 Enzymes involved in fatty acid metabolism are dysregulated in bronchial epithelial 
cells from asthma patients.  
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Table 1. Patient Demographics 
Obese                                  No                  No                   No                  Yes                Yes                 Yes 
Asthma                No      Mild/Moderate     Severe               No     Mild/Moderate    Severe         
n=                                         40                   26                   15                    40                 20                   20             
Age (S.D.)                     38.8 (12.1)    39.7 (12.3)     37.7 (9.9)      44.1 (13.8)    47.5 (10.6)    41.9 (12.2)     
BMI (S.D.)                      22.2 (1.4)      22.8 (1.6)      23.1 (1.1)      36.0 (4.5)      34.9 (4.8)       35.1 (6.0)                                            
Male/Female                  15/25             12/14               6/9                15/25             5/15             10/10           
Smoker (%)                      13 (33)           4 (15)             3 (20)             16 (40)           5 (25)            2 (10)           
Alcohol U/wk (S.D.)       2.3 (2.2)        2.5 (3.5)         2.5 (2.9)          1.8 (2.4)       1.4 (2.0)       2.0 (3.1)        
FEV1 % (S.D.)                /               80.1 (8.8)       71.1 (9.1)                /            76.6 (7.3)     66.4 (12.3)     
Allergy (%)                           /                  20 (77)          13 (87)                   /              15 (75)          16 (80)         
Daily ICS (%)                        /                  21 (81)         15 (100)                  /              15 (75)         20 (100)        
Daily ICS dose (S.D.)1         /               416 (342)      1165 (641)               /           422 (353)      1470 (577)     
Oral steroids (%)                 /                   0 (0)              2 (13)                    /                0 (0)             7 (35)           
SABA (%)                              /                  12 (46)           8 (53)                    /              12 (60)          11 (55)         
LABA (%)                              /                  14 (54)          12 (80)                   /               9 (55)            19 (95)        
Daily LABA dose (S.D.)2     /                  43 (46)          93 (59)                   /              45 (49)          128 (81)      
Anti-histamines (%)           /                  15 (58)          10 (66)                   /              10 (50)           15 (75)        
Leukotriene receptor 
antagonist (%)                /                  11 (42)          12 (80)                   /               9 (45)            15 (75)        
Daytime asthma  
symptoms >2 times(%)?   /       2 (8)            9 (60)                    /             2 (10)            13 (65)        
Exercise/activity limited  
due to asthma(%)?            /      5 (19)           12 (80)           /                7 (35)            15 (75)        
Waking at night due  
to asthma symptoms(%)? /       1 (4)            11 (73)                  /                3 (15)            14 (70)        
Use of rescue medications 
>2 times(%)?                /       0 (0)            13 (87)                  /              0 (0)             12 (60)        
1Dose of inhaled glucocorticosteroids calculated as a budesonide equivalent microgram/day 
2Dose of LABA calculated as a salmeterol equivalent microgram/day 
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